The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma

Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease

(2014) Kyuichi Kadota et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

The New Histologic Classification of Lung Primary Adenocarcinoma Subtypes Is a Reliable Prognostic Marker and Identifies Tumors With Different Mutation Status

(2014) Audrey Mansuet-Lupo et al.   CHEST

Micropapillary Mucinous Adenocarcinoma of the Lung: A Brief Case Report

(2014) In Ho Choi et al.   Korean Journal of Pathology

Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry

(2014) Esther Conde et al.   PLoS One

The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma

(2014) Yang Zhang et al.   Scientific Reports

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer

(2013) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

ALK Status Testing in Non–Small Cell Lung Carcinoma

(2013) Eugen C. Minca et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

A Comprehensive Comparative Analysis of the Histomorphological Features of ALK-Rearranged Lung Adenocarcinoma Based on Driver Oncogene Mutations: Frequent Expression of Epithelial-Mesenchymal Transition Markers than Other Genotype

(2013) Hyojin Kim et al.   PLoS One

Primary adenocarcinoma of lung: A pictorial review of recent updates

(2012) Anand Gaikwad et al.   EUROPEAN JOURNAL OF RADIOLOGY

Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas

(2012) Michiya Nishino et al.   MODERN PATHOLOGY

Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas

(2011) Akihiko Yoshida et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Clinicopathological features of lung adenocarcinoma with KRAS mutations

(2011) Seiichi Kakegawa et al.   CANCER

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

(2011) Vicki Leigh Keedy et al.   JOURNAL OF CLINICAL ONCOLOGY

A comparison of ARMS and direct sequencing for EGFR mutation analysis and Tyrosine Kinase Inhibitors treatment prediction in body fluid samples of Non-Small-Cell Lung Cancer patients

(2011) Yi Liu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

(2011) William D. Travis et al.   Journal of Thoracic Oncology

The potential for crizotinib in non-small cell lung cancer: a perspective review

(2011) Yung-Jue Bang   Therapeutic Advances in Medical Oncology

Frequency of EGFR and KRAS Mutations in Japanese Patients with Lung Adenocarcinoma with Features of the Mucinous Subtype of Bronchioloalveolar Carcinoma

(2010) Akito Hata et al.   Journal of Thoracic Oncology

EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues

(2009) Maria Paola Martelli et al.   AMERICAN JOURNAL OF PATHOLOGY

Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene

(2009) Tsuyoshi Takahashi et al.   ANNALS OF SURGICAL ONCOLOGY

TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS

(2009) Daisy Wing-Sze Wong et al.   CANCER

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib

(2009) Marie Wislez et al.   LUNG CANCER

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset

(2009) Kentaro Inamura et al.   MODERN PATHOLOGY